NICE recommends Targaxan (rifaximin) for treatment of hepatic encephalopathy- Norgine
The National Institute for Health and Care Excellence has published positive final draft guidance and recommended that Targaxan (rifaximin) from Norgine be approved for use on the NHS for treatment of hepatic encephalopathy (HE), a brain condition caused by liver failure that affects around 10,000 patients in the UK.
Comment: Treatment is extremely limited for patients with HE with no other new options being made available since lactulose was launched in 1969. Norgine BV holds a licence from Alfa Wassermann in Europe and Australia to market Xifaxan /Xifaxanta and in the Middle East. A pivotal trial showed a 58% relative risk of breakthrough episodes of overt HE and a 50% relative reduction in the risk of hospitalisations in patients given the drug.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins